Observational study to examine the burden of chronic anemia in
myelodysplastic syndromes and beta-thalassemia
SUMMIT, N.J. & SEATTLE--(BUSINESS WIRE)--
Celgene Corporation (NASDAQ: CELG) and Sage Bionetworks today announced
a collaboration to develop an iPhone application utilizing the Apple
ResearchKit framework to improve the understanding of the burden of
disease for patients living with chronic anemia due to myelodysplastic
syndromes (MDS) or beta-thalassemia.
Smartphone-based apps like Sage Bionetworks' mPower for Parkinson's
disease are increasingly being utilized as a tool by clinical study
researchers to collect and analyze increasing volumes of
patient-reported data in order to better capture and understand disease
burden better and to improve therapeutic developments. Smartphone
clinical study apps also enable the return communication of important
study information to the patient participants.
"We stand at a point where technology is unlocking the ability to
capture patient reported outcomes," said Michael Pehl, President,
Hematology & Oncology for Celgene. "Through our collaboration with Sage
Bionetworks and the evolving capability of smartphones and wearables as
robust data collection devices, we believe we will be able to provide
important new insights for patients with MDS and beta-thalassemia. We
are pleased to be working alongside Sage Bionetworks and the patient
community on this important project."
Celgene and Sage Bionetworks have chosen to address chronic anemia
caused by myelodysplastic syndromes and beta-thalassemia. These diseases
impose a great burden on affected individuals that is difficult to
understand and quantify, and typically have clinical endpoints outside
traditional measures. The collaboration seeks to move to a paradigm
where this and other information like physiological testing are
collected on a multi-dimensional and regular basis.
Already a leader in MDS, Celgene is currently developing three assets in
the clinic across myelodysplastic syndromes and beta-thalassemia
(CC-486, luspatercept, and enasidenib (AG-221/CC-90007)).
In addition to helping collect difficult to quantify data, the new
mobile study will collect neurological assessments of patients using
cognitive testing software from BrainBaseline, a leading technology for
the self-assessment of cognitive performance. The app will also be an
important channel for two-way communication and support for patients
living with their disease - allowing them to understand their physical
functioning and other symptoms of anemia.
Dr. Lara Mangravite, President of Sage Bionetworks stated, "We are
thrilled to partner with Celgene to explore the use of sensor-based
technologies to quantify the daily burden of disease in patients with
chronic anemia. This is a first of its kind exploration from which we
hope to gain insights that can be used to understand the impact of
Celgene and Sage Bionetworks are working closely with the MDS Foundation
and Cooleys Anemia Foundation (www.thalassemai.org)
in defining the right elements for capture in the application to ensure
patient relevance and applicability.
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of innovative therapies for
the treatment of cancer and inflammatory diseases through
next-generation solutions in protein homeostasis, immuno-oncology,
epigenetics, immunology and neuro-inflammation. For more information,
please visit www.celgene.com.
Follow Celgene on Social Media: @Celgene, Pinterest, LinkedIn, FaceBook and YouTube.
About Sage Bionetworks (www.sagebase.org)
Sage Bionetworks is a nonprofit biomedical research organization,
founded in 2009, with a vision to promote innovations in personalized
medicine by enabling a community-based approach to scientific inquiries
and discoveries. In pursuit of this Mission, Sage Bionetworks is working
with others to assemble an information Commons for biomedicine that (1)
is supported by an open compute space (Synapse: www.synapse.org),
(2) supports open research collaborations and innovative DREAM
Challenges, and (3) empowers citizens and patients with the tools to
partner with researchers and share their data through Sage's BRIDGE
in order to drive the research studies that matter most to them.
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," "outlook" and
similar expressions. Forward-looking statements are based on
management's current plans, estimates, assumptions and projections, and
speak only as of the date they are made. Celgene undertakes no
obligation to update any forward-looking statement in light of new
information or future events, except as otherwise required by law.
Forward-looking statements involve inherent risks and uncertainties,
most of which are difficult to predict and are generally beyond
Celgene's control. Actual results or outcomes may differ materially from
those implied by the forward-looking statements as a result of the
impact of a number of factors, many of which are discussed in more
detail in Celgene's Annual Report on Form 10-K and other reports filed
with the Securities and Exchange Commission.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161018005868/en/
Source: Celgene Corporation
News Provided by Acquire Media